Kimia Biosciences Ltd

Financial results and audit review

• Unaudited standalone Q1 2026 results approved by Board (quarter ended 30 Jun 2026).
• Revenue from operations: 2,072.25; total income: 2,080.31 (quarter ended 30 Jun 2026).
• Profit after tax: 35.58; earnings per share: 0.08 (quarter ended 30 Jun 2026).
• Audit Committee reviewed; board approved results on August 10, 2026.
• Limited Review Report by Neeraj Arora and Associates; no material misstatement observed.
• Single Pharmaceuticals segment; no reportable segment per Ind AS 108.

Audit opinion

• Standalone audited financial results for quarter and year ended March 31, 2026.
• Auditor issued an unmodified opinion on the standalone financial statements.
• Internal financial controls over financial reporting were found adequate and effective.

Financials

• Audited standalone results cover the year ended March 31, 2026.
• Auditor confirmed the statements present a true and fair view.
• The company did not pay any dividend during FY26.

R&D and accounting

• Company operates a DSIR-recognized R&D facility at Bhondsi, Gurugram.
• R&D focuses on new products, process improvement, cost optimization, and new APIs.
• Certain R&D costs were reassessed for capitalization under Ind AS 38.

Working capital and debt

• Working capital limits were sanctioned by Kotak Mahindra Bank.
• Sanctioned limits were ₹15.60 crore and ₹14.00 crore, with ₹8.71 crore and ₹14.00 crore outstanding.
• Auditor reported no default in repayment of loans or interest.

Capital structure

• Preference share capital of ₹8.00 crore was redeemed during Q1 and Q2 FY26.
• Redemption was stated to be duly authorized and compliant with the Companies Act.

Contingencies and compliance

• Pending litigations disclosed include Punjab VAT penalty, income tax demand, and TDS penalties.
• Auditor noted no material uncertainty over the company meeting liabilities within one year.
• No fraud, whistleblower complaints, or cash losses were reported for FY26.

Business

• Kimia Biosciences is a pharmaceutical company.
• Its R&D facility develops new products, processes, and active pharmaceutical ingredients.